The relationship between bile acid and hypertension

doi:10.3877/cma.j.issn.2095-8757.2021.01.010

Abstract

Abstract:

Hypertension is the most common chronic disease and the main risk factor of cardiovascular disease. At present, the etiology and pathogenesis of essential hypertension has not been fully elucidated. Further exploration of its related factors has great clinical significance for the prevention and treatment of cardiovascular disease. Bile acids are endogenous agonists of farnesol X receptor and endogenous inhibitors of 11 β - hydroxysteroid dehydrogenase, which may be involved in the occurrence and progress of cardiovascular diseases such as essential hypertension. This article reviews the relationship between bile acids and cardiovascular diseases such as hypertension, in order to provide reference for clinical practice.

Key words: Bile acids, Hypertension, Cardiovascular disease, Farnesoid X receptor, 11 β-hydroxysteroid dehydrogenase

Dan Lu, Ningyuan Fang, Haiya Wang. The relationship between bile acid and hypertension[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2021, 08(01): 41-44.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2021.01.010

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2021/V08/I01/41

References 35

[1]	Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm[J]. Nucl Recept Signal, 2010, 8:e005.
[2]	Funabashi M, Grove TL, Wang M, et al. A metabolic pathway for bile acid dehydroxylation by the gut microbiome[J]. Nature, 2020, 582(7813):566-570.
[3]	Marin JJ, Macias RI, Briz O, et al. Bile acids in physiology, pathology and pharmacology[J]. Curr Drug Metab, 2015, 17(1):4-29.
[4]	Perez MJ, Briz O. Bile-acid-induced cell injury and protection[J]. World J Gastroenterol, 2009, 15(14):1677-1689.
[5]	Fiorucci S, Distrutti E. Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders[J]. Trends Molecul Med, 2015, 21(11):702-714.
[6]	Juřica J, Dovrtělová G, Nosková K, et al. Bile Acids, Nuclear Receptors and Cytochrome P450[J]. Physiol Res, 2016, 65(Suppl 4):S427-S440.
[7]	Chiang JYL. Bile acids: Regulation of synthesis[J]. J Lipid Res, 2009, 50(10):1955.
[8]	Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: Natural ligands for an orphan nuclear receptor[J]. Science, 1999, 284(5418):1365-1368.
[9]	Ma H, Patti ME. Bile acids, obesity, and the metabolic syndrome[J]. Best Pract Res Clin Gastroenterol, 2014, 28(4):573-583.
[10]	Ferrer SC, Ehret G, Pechèrebertschi A. [Screening and management of hypertension in elderly][J]. Rev Med Suisse, 2015, 11(485):1638, 1640-1644.
[11]	刘力生.中国高血压防治指南2010[J].中华心血管病杂志，2011，39(7):42-93.
[12]	Li Y, Yang L, Wang L, et al. Burden of hypertension in China: A nationally representative survey of 174,621 adults[J]. Int J Cardiol, 2017, 227:516-523.
[13]	陈义林.原发性高血压患者血清总胆汁酸和尿酸水平的变化[J].安徽医药，2007，11(7):622-623.
[14]	林青，许少锋.血浆总胆汁酸与原发性高血压的关系[J].福建医科大学学报，2001，35(2):171-173.
[15]	庄梅.血清总胆汁酸水平对原发性高血压致病作用的探讨[J].贵州医药，2002，26(6):498-499.
[16]	张永生，吴平生，刘伊丽.动态血压监测高血压病患者血压及其与血浆总胆汁酸水平的关系[J].中国现代医学杂志，1998，8(11):45.
[17]	张永生，吴平生.胆汁酸对血压影响的多面性及其可能机制[J].中国现代医学杂志, 2000，10(6):33-34.
[18]	李易，蔡大润，包有生，等.总胆汁酸在高血压病中的作用初探[J].临床荟萃，1999，14(7):292-292.
[19]	徐辰祺，卜军，何奔.胆汁酸在心血管疾病中的作用[J].生理科学进展，2015，46(6):424-428.
[20]	Friedrich LC. 11-βhydroxysteroid dehydrogenase-2 and salt-sensitive hypertension[J]. Circulation, 2016, doi:10.1161/CIRCULATIONAHA.116.022038.
[21]	Yau M, Haider S, Khattab A, et al. Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency[J]. Proc Natl Acad Sci USA, 2017, 114(52):E11248-E11256.
[22]	Morris DJ, Souness GW. Endogenous 11 beta-hydroxysteroid dehydrogenase inhibitors and their role in glucocorticoid Na⁺ retention and hypertension[J]. Endocr Res, 1996, 22(4):793-801.
[23]	Li C, Li J, Weng X, et al. Farnesoid X receptor agonist CDCA reduces blood pressure and regulates vascular tone in spontaneously hypertensive rats[J]. J Am Soc Hypertens, 2015, 9(7):507-516.
[24]	Mazancová K, Miksík I, Kunes J, et al. Sexual dimorphism of 11 beta-hydroxysteroid dehydrogenase in hypertensive and normotensive rats[J]. Hypertens Res, 2003, 26(4):333-338.
[25]	Kosicka K, Cymerys M, Majchrzak-Celińska A, et al. 11β-Hydroxysteroid dehydrogenase type 2 in hypertension: comparison of phenotype and genotype analysis[J]. J Hum Hypertens, 2013, 27(8):510-515.
[26]	Evans LC, Ivy JR, Wyrwoll C, et al. Conditional deletion of hsd11b2 in the brain causes salt appetite and hypertension[J]. Circulation, 2016, 133(14):1360-1370.
[27]	Al-Salami H, Mamo JC, Mooranian A, et al. Long-term supplementation of microencapsulated ursodeoxycholic acid prevents hypertension in a mouse model of insulin resistance[J]. Exp Clin Endocrinol Diabetes, 2016, 125(1):28-32.
[28]	Charach G, Argov O, Geiger K, et al. Diminished bile acids excretion is a risk factor for coronary artery disease: 20-year follow up and long-term outcome[J]. Therap Adv Gastroenterol, 2018, 11:1756283X1774342.
[29]	徐冬新，傅颖.冠状动脉粥样硬化性心脏病患者血清总胆汁酸、超敏C反应蛋白、同型半胱氨酸、血脂水平变化的相关性研究[J].中国卫生检验杂志，2016，26(17):2503-2505.
[30]	公言伟，李建国，王全义.冠心病患者血清总胆汁酸水平与冠状动脉病变严重程度的相关性研究[J].中西医结合心血管病电子杂志，2015，3(16):63-64.
[31]	闫静静，范慧倩，杨玲.胆汁酸与心律失常[J].中华肝脏病杂志，2020，28(4):361-364.
[32]	Vasavan T, Ferraro E, Ibrahim E, et al. Heart and bile acids-Clinical consequences of altered bile acid metabolism[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B):1345-1355.
[33]	Cck M, Ueland T, Broch K, et al. Increased secondary/primary bile acid-ratio in chronic heart failure[J]. J Cardiac Fail, 2017, 23(9):666-671.
[34]	单瑞，杨培根.老年慢性心衰患者血清胆汁酸水平与炎症因子及心室重构的关系[J].天津医药，2018，46(1):42-45.
[35]	Desai M, Mathur B, Eblimit Z, et al. Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart[J]. Hepatology, 2017, 65(1):189-201.

Please choose a citation manager

Content to export